These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37877561)

  • 41. Adjuvant treatments for locally advanced differentiated thyroid cancer: a nationwide survey in Japan.
    Kawamoto T; Yasuda K; Ito Y; Zenda S; Sakanaka K; Shikama N; Nakamura N; Mizowaki T
    Endocr J; 2023 Oct; 70(10):999-1003. PubMed ID: 37779083
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differentiated thyroid cancer theranostics: radioiodine and beyond.
    Choudhury PS; Gupta M
    Br J Radiol; 2018 Nov; 91(1091):20180136. PubMed ID: 30260232
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influence of the first radioactive iodine ablation on peripheral complete blood count in patients with differentiated thyroid cancer.
    Hu T; Meng Z; Zhang G; Jia Q; Tan J; Zheng W; Wang R; Li X; Liu N; Zhou P; Upadhyaya A
    Medicine (Baltimore); 2016 Aug; 95(35):e4451. PubMed ID: 27583853
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Determining patient selection tool and response predictor for outpatient 30 mCi radioiodine ablation dose in non-metastatic differentiated thyroid carcinoma: a Japanese perspective.
    Higuchi T; Achmad A; Binh DD; Bhattarai A; Tsushima Y
    Endocr J; 2018 Mar; 65(3):345-357. PubMed ID: 29343651
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Higher administered activities of radioactive iodine are associated with less structural persistent response in older, but not younger, papillary thyroid cancer patients with lateral neck lymph node metastases.
    Sabra MM; Grewal RK; Ghossein RA; Tuttle RM
    Thyroid; 2014 Jul; 24(7):1088-95. PubMed ID: 24559250
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized trials on radioactive iodine ablation of thyroid remnants for thyroid carcinoma--a critique.
    Roos DE; Smith JG
    Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):493-5. PubMed ID: 10348276
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008.
    Sacks W; Fung CH; Chang JT; Waxman A; Braunstein GD
    Thyroid; 2010 Nov; 20(11):1235-45. PubMed ID: 21062195
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of different doses of radioactive iodine for remnant ablation on successful ablation and on long-term recurrences in patients with differentiated thyroid carcinoma.
    Kim EY; Kim TY; Kim WG; Yim JH; Han JM; Ryu JS; Hong SJ; Yoon JH; Gong G; Kim WB; Shong YK
    Nucl Med Commun; 2011 Oct; 32(10):954-9. PubMed ID: 21849927
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy.
    Vassilopoulou-Sellin R; Schultz PN; Haynie TP
    Cancer; 1996 Aug; 78(3):493-501. PubMed ID: 8697396
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Radioiodine lobar ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer.
    Bal CS; Kumar A; Pant GS
    Nucl Med Commun; 2003 Feb; 24(2):203-8. PubMed ID: 12548045
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differentiated thyroid carcinoma in a juvenile patient.
    Khan MU; Nawaz MK; Saadullah M; Syed AA; Hussain R; Azhar R; Shah MA
    Clin Nucl Med; 2008 May; 33(5):319-20. PubMed ID: 18431142
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A risk-adapted approach to the use of radioactive iodine and external beam radiation in the treatment of well-differentiated thyroid cancer.
    Tuttle RM; Rondeau G; Lee NY
    Cancer Control; 2011 Apr; 18(2):89-95. PubMed ID: 21451451
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Single Radioactive Iodine Treatment Has a Deleterious Effect on Ovarian Reserve in Women with Thyroid Cancer: Results of a Prospective Pilot Study.
    Yaish I; Azem F; Gutfeld O; Silman Z; Serebro M; Sharon O; Shefer G; Limor R; Stern N; Tordjman KM
    Thyroid; 2018 Apr; 28(4):522-527. PubMed ID: 29466932
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Unexpected radioactive iodine accumulation on whole-body scan after I-131 ablation therapy for differentiated thyroid cancer.
    Iwano S; Ito S; Kamiya S; Ito R; Kato K; Naganawa S
    Nagoya J Med Sci; 2020 May; 82(2):205-215. PubMed ID: 32581401
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Low iodine diet in differentiated thyroid cancer: a review.
    Li JH; He ZH; Bansal V; Hennessey JV
    Clin Endocrinol (Oxf); 2016 Jan; 84(1):3-12. PubMed ID: 26118628
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans.
    Sabra MM; Grewal RK; Tala H; Larson SM; Tuttle RM
    Thyroid; 2012 Sep; 22(9):877-83. PubMed ID: 22827641
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Incidence of radiation thyroiditis and thyroid remnant ablation success rates following 1110 MBq (30 mCi) and 3700 MBq (100 mCi) post-surgical 131I ablation therapy for differentiated thyroid carcinoma.
    Cherk MH; Kalff V; Yap KS; Bailey M; Topliss D; Kelly MJ
    Clin Endocrinol (Oxf); 2008 Dec; 69(6):957-62. PubMed ID: 18419785
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recombinant human thyroid-stimulating hormone to stimulate 131-I uptake for remnant ablation and adjuvant therapy.
    Sabra MM; Tuttle RM
    Endocr Pract; 2013; 19(1):149-56. PubMed ID: 23186980
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Radioactive Iodine for Papillary Thyroid Carcinoma.
    Chan WWL; Kwong DLW
    Methods Mol Biol; 2022; 2534():225-241. PubMed ID: 35670979
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
    Dehbi HM; Mallick U; Wadsley J; Newbold K; Harmer C; Hackshaw A
    Lancet Diabetes Endocrinol; 2019 Jan; 7(1):44-51. PubMed ID: 30501974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.